X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (990) 990
Publication (38) 38
Government Document (7) 7
Newsletter (7) 7
Book / eBook (3) 3
Book Chapter (1) 1
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (623) 623
chlorobenzenes - pharmacology (424) 424
rats (394) 394
male (392) 392
female (296) 296
humans (264) 264
pharmacology & pharmacy (193) 193
chlorobenzenes - toxicity (174) 174
chlorobenzenes - metabolism (159) 159
toxicology (158) 158
index medicus (149) 149
time factors (125) 125
mice (124) 124
rats, inbred strains (116) 116
chlorobenzenes (110) 110
chlorobenzenes - administration & dosage (105) 105
hexachlorobenzene - pharmacology (101) 101
liver - drug effects (101) 101
liver - metabolism (89) 89
dose-response relationship, drug (79) 79
chlorobenzene (77) 77
hexachlorobenzene - metabolism (74) 74
microsomes, liver - enzymology (72) 72
adult (71) 71
chlorobenzenes - therapeutic use (69) 69
kinetics (69) 69
body weight - drug effects (65) 65
liver - enzymology (64) 64
organ size - drug effects (64) 64
middle aged (63) 63
chlorobenzenes - chemistry (60) 60
in vitro techniques (60) 60
porphyrias - chemically induced (60) 60
drug combinations (58) 58
benzyl alcohols - administration & dosage (57) 57
chlorobenzenes - pharmacokinetics (57) 57
administration, inhalation (56) 56
hexachlorobenzene - toxicity (54) 54
administration, oral (51) 51
cytochrome p-450 enzyme system - metabolism (50) 50
structure-activity relationship (50) 50
toxicity (49) 49
biotransformation (46) 46
enzyme induction - drug effects (46) 46
pulmonary disease, chronic obstructive - drug therapy (46) 46
analysis (44) 44
chlorobenzenes - adverse effects (44) 44
microsomes, liver - drug effects (42) 42
rats, inbred f344 (42) 42
aged (41) 41
metabolism (40) 40
tissue distribution (40) 40
biochemistry & molecular biology (39) 39
dogs (38) 38
phenobarbital - pharmacology (38) 38
vilanterol (38) 38
diet (37) 37
hexachlorobenzene (37) 37
benzyl alcohols - therapeutic use (35) 35
pregnancy (34) 34
chemistry, medicinal (33) 33
drug interactions (33) 33
environmental sciences (33) 33
microsomes, liver - metabolism (33) 33
oxidation-reduction (33) 33
species specificity (33) 33
porphyrins - metabolism (32) 32
rats, wistar (32) 32
respiratory system (32) 32
liver (31) 31
copd (30) 30
cytochrome p-450 enzyme system - biosynthesis (30) 30
rats, sprague-dawley (30) 30
safety (30) 30
carbon radioisotopes (29) 29
chlorobenzenes - chemical synthesis (29) 29
glutathione (29) 29
rabbits (29) 29
androstadienes - administration & dosage (28) 28
asthma (28) 28
mice, inbred c57bl (28) 28
research (28) 28
cells, cultured (27) 27
clinical trials as topic (27) 27
double-blind method (27) 27
glutathione - metabolism (27) 27
lung diseases, obstructive (27) 27
benzyl alcohols - adverse effects (26) 26
benzyl alcohols - pharmacology (26) 26
chemistry (26) 26
kidney - drug effects (26) 26
liver - pathology (26) 26
quinuclidines - administration & dosage (26) 26
biguanides - pharmacology (25) 25
bronchodilator agents - therapeutic use (25) 25
dichlorobenzene (25) 25
adrenergic beta-2 receptor agonists - administration & dosage (24) 24
chlorobenzenes - analysis (24) 24
chromatography, high pressure liquid (24) 24
enzyme induction (24) 24
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (941) 941
German (20) 20
Russian (13) 13
Polish (9) 9
Italian (7) 7
Japanese (6) 6
French (5) 5
Chinese (4) 4
Spanish (3) 3
Bulgarian (2) 2
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Mycoses, ISSN 0933-7407, 05/2016, Volume 59, Issue 5, pp. 281 - 290
Journal Article
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2014, Volume 9, pp. 687 - 695
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, p. e50716
Umeclidinium bromide (GSK573719; UMEC), a new long-acting muscarinic receptor antagonist (LAMA), is in development with vilanterol (GW642444; VI), a selective... 
Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Quinuclidines - administration & dosage | Adrenergic beta-2 Receptor Agonists - pharmacology | Chlorobenzenes - administration & dosage | Young Adult | Chlorobenzenes - pharmacokinetics | Drug Interactions | Adrenergic beta-2 Receptor Agonists - adverse effects | Dry Powder Inhalers - instrumentation | Muscarinic Antagonists - pharmacology | Benzyl Alcohols - pharmacology | Chlorobenzenes - pharmacology | Patient Safety | Adult | Muscarinic Antagonists - pharmacokinetics | Benzyl Alcohols - pharmacokinetics | Drug Therapy, Combination | Quinuclidines - adverse effects | Double-Blind Method | Quinuclidines - pharmacology | Cross-Over Studies | Muscarinic Antagonists - administration & dosage | Chlorobenzenes - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Quinuclidines - pharmacokinetics | Medicine, Experimental | Medical research | Respiratory agents | Lung diseases, Obstructive | Care and treatment | Heart beat | Health care | Drugs | Pharmacodynamics | Acetylcholine receptors (muscarinic) | Laboratories | Medical treatment | Lung diseases | Systematic review | Pharmacology | Vital signs | Assessments | Powder | Heart rate | Human subjects | Studies | Obstructive lung disease | Chronic obstructive pulmonary disease | Blood pressure | Safety | Pharmacokinetics | Potassium | Drug dosages
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2017, Volume 12, pp. 1903 - 1913
Journal Article
SCIENCE, ISSN 0036-8075, 02/2019, Volume 363, Issue 6429, pp. 875 - 875
Potassium (K+) channels have been evolutionarily tuned for activation by diverse biological stimuli, and pharmacological activation is thought to target these... 
CONDUCTANCE | K-2P | HERG | POTASSIUM CHANNELS | STRUCTURAL BASIS | HIGH-THROUGHPUT | BK CHANNELS | MULTIDISCIPLINARY SCIENCES | CONSTANT-PRESSURE | PARTICLE MESH EWALD | MOLECULAR-DYNAMICS SIMULATIONS | Xenopus | Tetrazoles - pharmacology | ortho-Aminobenzoates - chemistry | ortho-Aminobenzoates - pharmacology | Cricetulus | Humans | Crystallography, X-Ray | Thiourea - pharmacology | Large-Conductance Calcium-Activated Potassium Channels - chemistry | Tetrazoles - chemistry | Chlorobenzenes - pharmacology | Drug Design | HEK293 Cells | Chlorobenzenes - chemistry | Protein Domains | CHO Cells | ERG1 Potassium Channel - chemistry | Large-Conductance Calcium-Activated Potassium Channels - agonists | ERG1 Potassium Channel - agonists | Thiourea - chemistry | Molecular Dynamics Simulation | Animals | Tetrahydronaphthalenes - chemistry | Tetrahydronaphthalenes - pharmacology | Thiourea - analogs & derivatives | Ion Channel Gating - drug effects | Molecular dynamics | Analysis | Pharmaceutical research | Potassium channels | Research | Pharmacokinetics | Calcium | Epilepsy | Activation | Potassium conductance | Selectivity | Drug development | Crystallography | Channels | X-ray crystallography | Pain | Occupancy | Potassium channels (voltage-gated) | Gating | Calcium channels | Channel gating | Calcium channels (voltage-gated) | Pharmacology | Functional analysis | Resistance | Dynamic tests | Calcium conductance | Conductance | Potassium | Calcium ions
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 04/2017, Volume 195, Issue 7, pp. 881 - 888
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 10/2013, Volume 7, pp. 1201 - 1208
An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting beta(2)-agonist (LABA) combination appears to play an... 
Muscarinic antagonist | Dual bronchodilation | COPD | VILANTEROL | CHEMISTRY, MEDICINAL | MANAGEMENT | HEALTHY-SUBJECTS | PHARMACOLOGICAL CHARACTERIZATION | MUSCARINIC RECEPTORS | ACTING BETA-ADRENOCEPTOR AGONIST | LUNG-FUNCTION | OBSTRUCTIVE PULMONARY-DISEASE | muscarinic antagonist | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | dual bronchodilation | BRONCHODILATOR THERAPY | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Outcome Assessment (Health Care) | Humans | Benzyl Alcohols - administration & dosage | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Adrenergic beta-2 Receptor Agonists - pharmacology | Chlorobenzenes - administration & dosage | Forced Expiratory Volume | Quinuclidines - therapeutic use | Muscarinic Antagonists - pharmacology | Benzyl Alcohols - pharmacology | Chlorobenzenes - pharmacology | Adrenergic beta-2 Receptor Agonists - therapeutic use | Quinuclidines - pharmacology | Administration, Inhalation | Bronchodilator Agents - pharmacology | Muscarinic Antagonists - administration & dosage | Chlorobenzenes - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Delayed-Action Preparations | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Pharmaceutical research | Lung diseases, Obstructive | Drug therapy, Combination | Research | Drug therapy | Bronchodilation | Respiratory function | Acetylcholine receptors (muscarinic) | Lung diseases | Obstructive lung disease | New combinations | Bronchodilators | Chronic obstructive pulmonary disease
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, pp. e0176837 - e0176837
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 12/2016, Volume 10, pp. 4047 - 4060
The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an... 
Dry powder inhaler | Long-acting beta | Persistent asthma | Inhaled corticosteroid | Fluticasone furoate/vilanterol trifenatate | agonist | Combined inhaler | Asthma | persistent asthma | TO-MODERATE ASTHMA | CHEMISTRY, MEDICINAL | VILANTEROL TRIFENATATE | INHALED CORTICOSTEROID-THERAPY | ACTING BETA-ADRENOCEPTOR AGONIST | asthma | combined inhaler | dry powder inhaler | inhaled corticosteroid | fluticasone furoate/vilanterol trifenatate | DIFFICULT ASTHMA | CONTROLLED RANDOMIZED-TRIAL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | long-acting beta agonist | FUROATE 50 MCG | Anti-Asthmatic Agents - pharmacology | Benzyl Alcohols - chemistry | Drug Administration Schedule | Adrenergic beta-2 Receptor Agonists - chemistry | Humans | Administration, Inhalation | Adrenal Cortex Hormones - chemistry | Adrenal Cortex Hormones - pharmacology | Benzyl Alcohols - administration & dosage | Asthma - drug therapy | Adrenergic beta-2 Receptor Agonists - pharmacology | Chlorobenzenes - administration & dosage | Androstadienes - chemistry | Androstadienes - administration & dosage | Androstadienes - pharmacology | Dry Powder Inhalers - instrumentation | Benzyl Alcohols - pharmacology | Chlorobenzenes - pharmacology | Chlorobenzenes - chemistry | Adrenergic beta-2 Receptor Agonists - administration & dosage | Anti-Asthmatic Agents - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Anti-Asthmatic Agents - chemistry | Drug therapy, Combination | Fluticasone | Comparative analysis | Drug therapy | Corticoids | Respiratory therapy | Therapy | Signs and symptoms | Corticosteroids | Lung diseases | Medical services | Maintenance | FDA approval | Patients | Powder | Medicine | Historical account | Safety engineering | Obstructive lung disease | Chronic obstructive pulmonary disease | Adults | Inhalers | Drug dosages | Fluticasone furoate / vilanterol trifenatate | long-acting beta2 agonist (LABA) | dry powder inhaler (DPI) | inhaled corticosteroid (ICS)
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 06/2015, Volume 35, Issue 6, pp. 586 - 599
Study Objective To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) – a fixed‐dose combination of an... 
fluticasone furoate, inhaled corticosteroids | cortisol | systemic exposure | China | pharmacodynamics | vilanterol | pharmacokinetics | long‐acting beta2 agonists | agonists | long-acting beta | fluticasone furoate | EFFICACY | SAFETY | MU-G | long-acting beta agonists |